A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects

NCT01812538 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Ventricular Repolarization

Interventions

DRUG: DIC075V

Sponsor

Hospira, now a wholly owned subsidiary of Pfizer